Compare Cintas Corporation (CTAS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Cintas Corporation trades at $204.22 (market cap $82.15B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Cintas Corporation is far larger — about 1045.8× Inovio Pharmaceuticals Inc's market cap, and Cintas Corporation pays a 1.01% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTAS | INO | |
|---|---|---|
Market Cap | $82.15B | $78.55M |
Sector | Industrials | Health |
52-Week High | $225.10 | $2.87 |
52-Week Low | $163.55 | $0.66 |
Enterprise Value | $84.56B | $49.56M |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $204.86, up 1.06% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The company reported strong Q2 2026 EPS of $1.29, exceeding expectations, and maintains robust fundamentals with a 17.75% net income margin and 40.59% ROE. Revenue growth is steady, reaching $10.34B in 2025, supported by consistent profitability and a dividend payout.
The outlook is positive, with a consensus price target of $225.83 implying ~10% upside, though high valuation ratios (P/E 41.81) and competitive pressures pose risks. Institutional interest is strong, with recent upgrades, but investors should monitor debt levels and economic sensitivity.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
